The VBI Vaccines, Inc. – (VBIV) Stock Rating Lowered by TheStreet

The VBI Vaccines, Inc. – (VBIV) Stock Rating Lowered by TheStreet

A number of other brokerages have also recently commented on VBIV. Noble Financial reiterated a “buy” rating on shares of VBI Vaccines, Inc. – in a research note on Friday, May 5th. Zacks Investment Research cut VBI Vaccines, Inc. – from a “buy” rating to a “hold” rating in a research note on Friday. Four research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $5.38.

VBI Vaccines, Inc. – (NASDAQ:VBIV) was downgraded by investment analysts at TheStreet from a “c-” rating to a “d+” rating in a report issued on Wednesday.

Shares of VBI Vaccines, Inc. – (NASDAQ VBIV) opened at 4.56 on Wednesday. The company’s 50 day moving average price is $4.37 and its 200-day moving average price is $4.22. VBI Vaccines, Inc. – has a 52 week low of $2.75 and a 52 week high of $6.60. The firm’s market capitalization is $182.67 million. A number of hedge funds and other institutional investors have recently made changes to their positions in VBIV. Geode Capital Management LLC raised its position in shares of VBI Vaccines, Inc. – by 31.0% in the first quarter. Geode Capital Management LLC now owns 22,468 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 5,317 shares in the last quarter. Bank of Montreal Can raised its position in shares of VBI Vaccines, Inc. – by 66.5% in the first quarter. Bank of Montreal Can now owns 58,398 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 23,322 shares in the last quarter. Morgan Stanley raised its position in shares of VBI Vaccines, Inc. – by 28,153.6% in the first quarter. Morgan Stanley now owns 62,723 shares of the biopharmaceutical company’s stock valued at $344,000 after buying an additional 62,501 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of VBI Vaccines, Inc. – during the first quarter valued at about $383,000. Finally, EAM Investors LLC bought a new position in shares of VBI Vaccines, Inc. – during the first quarter valued at about $414,000. 22.11% of the stock is owned by institutional investors and hedge funds.

VBI Vaccines, Inc. – Company Profile VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:VBIV”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for VBI Vaccines Inc. – Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for VBI Vaccines Inc. – and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment